RepliCel Life Financials

RP Stock  CAD 0.01  0.00  0.00%   
We recommend to use RepliCel Life Sciences fundamental analysis to find out if markets are presently mispricing the firm. Put it differently this technique allows you to confirm available drivers of RepliCel Life Sciences as well as the relationship between them. We were able to interpolate twenty-nine available financial ratios for RepliCel Life Sciences, which can be compared to its competitors. The stock experiences a normal downward trend, but the immediate impact on correlations cannot be determined at the moment . Check odds of RepliCel Life to be traded at C$0.0099 in 90 days. Key indicators impacting RepliCel Life's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio0.08450.0889
Notably Down
Slightly volatile
  
Please note, the imprecision that can be found in RepliCel Life's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of RepliCel Life Sciences. Check RepliCel Life's Beneish M Score to see the likelihood of RepliCel Life's management manipulating its earnings.

RepliCel Life Stock Summary

RepliCel Life competes with JPMorgan Chase, Bank of America, Toronto Dominion, Royal Bank, and Royal Bank. RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada. REPLICEL LIFE operates under Biotechnology classification in Canada and is traded on TSX Venture Exchange.
Foreign Associate
  USA
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentCanada Stock View All
ExchangeTSX Venture Exchange
ISINCA76027P4006
Business Address570 Granville Street,
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.replicel.com
Phone604 248 8730
CurrencyCAD - Canadian Dollar
You should never invest in RepliCel Life without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of RepliCel Stock, because this is throwing your money away. Analyzing the key information contained in RepliCel Life's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

RepliCel Life Key Financial Ratios

There are many critical financial ratios that RepliCel Life's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that RepliCel Life Sciences reports annually and quarterly.

RepliCel Life Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets505.5K421.0K591.8K798.2K287.8K273.4K
Net Debt425.4K41.7K(186.9K)(372.1K)754.0K791.7K
Retained Earnings(36.6M)(38.2M)(42.2M)(43.0M)(43.3M)(41.1M)
Accounts Payable640.3K1.3M602.0K817.9K416.0K472.3K
Cash23.9K34.4K221.2K413.0K59.2K56.2K
Net Receivables51.9K63.6K61.2K82.2K38.0K39.0K
Total Liab4.9M5.5M7.4M6.7M4.8M5.1M
Total Current Assets233.2K185.7K393.0K635.7K162.1K154.0K
Short Term Debt449.3K47.3K611.4K689.3K813.2K853.8K
Common Stock27.5M28.5M30.3M31.7M33.1M20.0M
Other Current Liab107.3K517.8K106.6K211.8K239.5K432.0K
Other Assets266.2K230.8K195.5K1.01.151.09
Other Current Assets128.7K70.5K93.4K123.2K47.7K89.2K
Net Tangible Assets(1.9M)(4.4M)(5.1M)(6.8M)(6.2M)(5.9M)
Net Invested Capital(2.9M)(5.0M)(6.8M)(5.9M)(5.3M)(5.6M)
Net Working Capital(1.2M)(2.1M)(1.3M)(1.4M)(1.3M)(1.4M)
Capital Stock29.0M28.5M30.3M31.7M36.4M32.6M

RepliCel Life Key Income Statement Accounts

201920202021202220232024 (projected)
Interest Expense141.4K176.1K5.5K6.7K149.1K156.6K
Operating Income(2.9M)(1.1M)(3.2M)(191.4K)(1.4M)(1.5M)
Ebit(2.9M)(1.1M)(3.2M)(191.4K)(1.4M)(1.5M)
Ebitda(2.9M)(1.1M)(3.2M)(190.6K)(1.4M)(1.5M)
Income Before Tax(3.0M)(1.6M)(4.1M)(743.2K)(311.7K)(327.3K)
Net Income(3.0M)(1.6M)(4.1M)(743.2K)(311.7K)(327.3K)
Income Tax Expense44.0K183.5K(867.9K)1.2M(1.0)(1.05)
Research Development2.2M819.4K1.1M624.0K526.4K500.1K
Net Interest Income(92.0K)(175.7K)69.0(6.7K)(1.1K)(1.1K)
Interest Income92.0K358.069.043.0725.0688.75

RepliCel Life Key Cash Accounts

201920202021202220232024 (projected)
Change In Cash(2.4M)10.4K186.8K191.8K(353.9K)(336.2K)
Free Cash Flow(2.8M)(765.2K)(2.5M)(1.4M)(1.4M)(1.5M)
Other Non Cash Items(285.1K)(281.1K)560.6K(1.6M)(1.1M)(1.0M)
Net Income(3.0M)(1.6M)(4.1M)(743.2K)(311.7K)(327.3K)
End Period Cash Flow23.9K34.4K221.2K413.0K59.2K56.2K
Depreciation2.2K1.6K1.1K839.01.5K1.4K
Change To Netincome232.2K(224.8K)(102.5K)1.9M2.2M2.3M

RepliCel Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining RepliCel Life's current stock value. Our valuation model uses many indicators to compare RepliCel Life value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across RepliCel Life competition to find correlations between indicators driving RepliCel Life's intrinsic value. More Info.
RepliCel Life Sciences is currently regarded as top stock in return on asset category among its peers. It also is currently regarded as top stock in profit margin category among its peers . At this time, RepliCel Life's Net Loss is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the RepliCel Life's earnings, one of the primary drivers of an investment's value.

RepliCel Life Sciences Systematic Risk

RepliCel Life's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. RepliCel Life volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on RepliCel Life Sciences correlated with the market. If Beta is less than 0 RepliCel Life generally moves in the opposite direction as compared to the market. If RepliCel Life Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one RepliCel Life Sciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of RepliCel Life is generally in the same direction as the market. If Beta > 1 RepliCel Life moves generally in the same direction as, but more than the movement of the benchmark.

RepliCel Life Sciences Total Assets Over Time

Today, most investors in RepliCel Life Stock are looking for potential investment opportunities by analyzing not only static indicators but also various RepliCel Life's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of RepliCel Life growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.16

At this time, RepliCel Life's Price Earnings To Growth Ratio is fairly stable compared to the past year.

RepliCel Life December 18, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of RepliCel Life help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of RepliCel Life Sciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of RepliCel Life Sciences based on widely used predictive technical indicators. In general, we focus on analyzing RepliCel Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build RepliCel Life's daily price indicators and compare them against related drivers.

Additional Tools for RepliCel Stock Analysis

When running RepliCel Life's price analysis, check to measure RepliCel Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RepliCel Life is operating at the current time. Most of RepliCel Life's value examination focuses on studying past and present price action to predict the probability of RepliCel Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RepliCel Life's price. Additionally, you may evaluate how the addition of RepliCel Life to your portfolios can decrease your overall portfolio volatility.